PDF(Pubmed)
Abstract：
UNASSIGNED: We assessed the effect of a closed-loop oxygen control system in pediatric patients receiving high-flow nasal oxygen therapy (HFNO).
UNASSIGNED: A multicentre, single-blinded, randomized, and cross-over study. Patients aged between 1 month and 18 years of age receiving HFNO for acute hypoxemic respiratory failure (AHRF) were randomly assigned to start with a 2-h period of closed-loop oxygen control or a 2-h period of manual oxygen titrations, after which the patient switched to the alternative therapy. The endpoints were the percentage of time spent in predefined SpO2 ranges (primary), FiO2, SpO2/FiO2, and the number of manual adjustments.
UNASSIGNED: We included 23 patients, aged a median of 18 (3-26) months. Patients spent more time in a predefined optimal SpO2 range when the closed-loop oxygen controller was activated compared to manual oxygen titrations [91⋅3% (IQR 78⋅4-95⋅1%) vs. 63⋅0% (IQR 44⋅4-70⋅7%)], mean difference [28⋅2% (95%-CI 20⋅6-37⋅8%); P < 0.001]. Median FiO2 was lower [33⋅3% (IQR 26⋅6-44⋅6%) vs. 42⋅6% (IQR 33⋅6-49⋅9%); P = 0.07], but median SpO2/FiO2 was higher [289 (IQR 207-348) vs. 194 (IQR 98-317); P = 0.023] with closed-loop oxygen control. The median number of manual adjustments was lower with closed-loop oxygen control [0⋅0 (IQR 0⋅0-0⋅0) vs. 0⋅5 (IQR 0⋅0-1⋅0); P < 0.001].
UNASSIGNED: Closed-loop oxygen control improves oxygenation therapy in pediatric patients receiving HFNO for AHRF and potentially leads to more efficient oxygen use. It reduces the number of manual adjustments, which may translate into decreased workloads of healthcare providers.
UNASSIGNED: [www.ClinicalTrials.gov], identifier [NCT05032365].
UNASSIGNED: A multicentre, single-blinded, randomized, and cross-over study. Patients aged between 1 month and 18 years of age receiving HFNO for acute hypoxemic respiratory failure (AHRF) were randomly assigned to start with a 2-h period of closed-loop oxygen control or a 2-h period of manual oxygen titrations, after which the patient switched to the alternative therapy. The endpoints were the percentage of time spent in predefined SpO2 ranges (primary), FiO2, SpO2/FiO2, and the number of manual adjustments.
UNASSIGNED: We included 23 patients, aged a median of 18 (3-26) months. Patients spent more time in a predefined optimal SpO2 range when the closed-loop oxygen controller was activated compared to manual oxygen titrations [91⋅3% (IQR 78⋅4-95⋅1%) vs. 63⋅0% (IQR 44⋅4-70⋅7%)], mean difference [28⋅2% (95%-CI 20⋅6-37⋅8%); P < 0.001]. Median FiO2 was lower [33⋅3% (IQR 26⋅6-44⋅6%) vs. 42⋅6% (IQR 33⋅6-49⋅9%); P = 0.07], but median SpO2/FiO2 was higher [289 (IQR 207-348) vs. 194 (IQR 98-317); P = 0.023] with closed-loop oxygen control. The median number of manual adjustments was lower with closed-loop oxygen control [0⋅0 (IQR 0⋅0-0⋅0) vs. 0⋅5 (IQR 0⋅0-1⋅0); P < 0.001].
UNASSIGNED: Closed-loop oxygen control improves oxygenation therapy in pediatric patients receiving HFNO for AHRF and potentially leads to more efficient oxygen use. It reduces the number of manual adjustments, which may translate into decreased workloads of healthcare providers.
UNASSIGNED: [www.ClinicalTrials.gov], identifier [NCT05032365].
摘要：
UNASSIGNED：我们评估了闭环氧气控制系统在接受高流量鼻氧治疗（HFNO）的儿科患者中的作用。
未经批准：多中心，单盲,随机化，和交叉学习。年龄在1个月至18岁之间的因急性低氧性呼吸衰竭（AHRF）接受HFNO的患者被随机分配开始进行2小时的闭环氧气控制或2小时的手动氧气滴定。之后，患者切换到替代疗法。终点是在预定义的SpO2范围（主要）中花费的时间百分比，FiO2、SpO2/FiO2和手动调整次数。
未经批准：我们纳入了23名患者，年龄中位数为18(3-26)个月。与手动氧气滴定相比，当激活闭环氧气控制器时，患者在预定义的最佳SpO2范围内花费的时间更多[91·3%（IQR78·4-95·1%）与63·0%(IQR44·4-70·7%)]，平均差[28·2%(95%-CI20·6-37·8%)；P<0.001]。FiO2中位数较低[33·3%（IQR26·6-44·6%）与42·6%(IQR33·6-49·9%)；P=0.07]，但中位数SpO2/FiO2较高[289（IQR207-348）与194（IQR98-317）；P=0.023]，具有闭环氧气控制。在闭环氧气控制下，手动调整的中位数较低[0·0（IQR0·0-0·0）与0·5(IQR0·0-1·0)；P<0.001]。
UASSIGNED：闭环氧控制可改善接受HFNO治疗AHRF的儿科患者的氧合治疗，并可能导致更有效的氧气使用。它减少了手动调整的次数，这可能会导致医疗保健提供者的工作量减少。
未经批准：[www.ClinicalTrials.gov],标识符[NCT05032365]。
未经批准：多中心，单盲,随机化，和交叉学习。年龄在1个月至18岁之间的因急性低氧性呼吸衰竭（AHRF）接受HFNO的患者被随机分配开始进行2小时的闭环氧气控制或2小时的手动氧气滴定。之后，患者切换到替代疗法。终点是在预定义的SpO2范围（主要）中花费的时间百分比，FiO2、SpO2/FiO2和手动调整次数。
未经批准：我们纳入了23名患者，年龄中位数为18(3-26)个月。与手动氧气滴定相比，当激活闭环氧气控制器时，患者在预定义的最佳SpO2范围内花费的时间更多[91·3%（IQR78·4-95·1%）与63·0%(IQR44·4-70·7%)]，平均差[28·2%(95%-CI20·6-37·8%)；P<0.001]。FiO2中位数较低[33·3%（IQR26·6-44·6%）与42·6%(IQR33·6-49·9%)；P=0.07]，但中位数SpO2/FiO2较高[289（IQR207-348）与194（IQR98-317）；P=0.023]，具有闭环氧气控制。在闭环氧气控制下，手动调整的中位数较低[0·0（IQR0·0-0·0）与0·5(IQR0·0-1·0)；P<0.001]。
UASSIGNED：闭环氧控制可改善接受HFNO治疗AHRF的儿科患者的氧合治疗，并可能导致更有效的氧气使用。它减少了手动调整的次数，这可能会导致医疗保健提供者的工作量减少。
未经批准：[www.ClinicalTrials.gov],标识符[NCT05032365]。
